Lonza: Luzhu Biotech Develops Recombinant Shingles Vaccine and Bispecific Antibody Using Lonza’s GS Xceed® Gene Expression System

  • Luzhu Biotech has entered into a license agreement to use Lonza’s GS Xceed® Gene expression system with GS piggyBac® transposon technology
  • Luzhu Biotech is developing a recombinant shingles vaccine and bispecific antibody therapeutic injection targeting relapsed or refractory B-cell non-Hodgkin’s lymphoma and B-cell leukemia, using licensed Lonza technologies

Basel, Switzerland and Beijing, China, April 25, 2022 – Beijing Luzhu Biotechnology Co., Ltd. (Luzhu Biotech) and Lonza, a global development and manufacturing partner for the pharmaceutical, biotechnology and nutritional industries, have entered into a research and commercial license agreement allowing Luzhu to use Lonza’s GS Xceed® Gene expression system with GS piggyBac® transposon technology. Luzhu Biotech is a biopharmaceutical company engaged in the research and development of a diverse pipeline of drug candidates for the prevention, control and treatment of human diseases.

Luzhu Biotech has obtained clinical trial approval for its recombinant shingles vaccine LZ901 used to prevent herpes zoster virus infection and suitable for susceptible adults over the age of 50. Made from recombinant varicella zoster virus glycoprotein E expressed in CHO cells, the LZ901 vaccine is free of preservatives and antibiotics. Luzhu Biotech is also in a clinical trial with its K193 antibody injection, a bispecific antibody directed against human CD19 and CD3 primarily used for the treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma and relapsed or refractory B-cell leukemia. . LZ901 vaccine and K193 antibody are expressed using Lonza’s GS system® with piggyBac™ transposon technology.

Licensing agreement with Lonza secures Luzhu Biotech’s access to GS Xceed® Gene Expression System, enabling the development of scalable, robust and reliable expression processes. Luzhu Biotech noted stable expression of their therapeutic bispecific vaccine and antibody using Lonza’s GS gene expression system®. the GS Xceed® Expression System Toolbox now also includes PiggyBac GS® transposon technologywhich preferentially targets stable regions of the genome associated with highly expressed genes. Peter Droc, Head of Pharmaceutical Licensing and Services, Lonza, commented: “The transition of Luzhu Biotech’s innovative candidates to clinical trials is a great step forward in next-generation molecules and vaccine development. At Lonza, we are committed to developing a toolkit of expression systems that help adapt to industry trends.flexible model is suitable for all types of businesses, so they can license the technology platform for internal use.”Jian Kong, CEO of Luzhu Biotech, commented:“Lonza’s GS Xceed Expression System is an easy-to-use mammalian cell protein expression system. We have successfully expressed and produced a variety of recombinant bispecific antibodies and viral proteins by this system. Viral antigens expressed by GS Xceed®show superior immunogenicity and the type of glycosylation covers quite well the types of viral proteins already available. The immunological results also showed that the recombinant shingles vaccine using Lonza’s formula GS Xceed®Expression System could stimulate animal immune system to induce good cellular immunity and humoral immunity.”


Lonza Group Ltd. published this content on April 25, 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unmodified, on April 25, 2022 06:08:10 UTC.

Comments are closed.